Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANIP Stock Forecast 2026-2027
$72.49
Current Price
$1.63B
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ANIP Price Targets
+71.1%
To High Target of $124.00
+55.9%
To Median Target of $113.00
+24.2%
To Low Target of $90.00
ANIP Price Momentum
-2.1%
1 Week Change
-6.3%
1 Month Change
+17.9%
1 Year Change
-8.2%
Year-to-Date Change
-27.1%
From 52W High of $99.50
+27.8%
From 52W Low of $56.71
📊 TOP ANALYST CALLS
Did ANIP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ANI Pharmaceuticals is one of their latest high-conviction picks.
Latest ANIP Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ANIP has a bullish consensus with a median price target of $113.00 (ranging from $90.00 to $124.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $72.49, the median forecast implies a 55.9% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Vamil Divan at Guggenheim, projecting a 71.1% upside. Conversely, the most conservative target is provided by Gregory Fraser at Truist Securities, suggesting a 24.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANIP Analyst Ratings
7
Buy
1
Hold
0
Sell
ANIP Price Target Range
Low
$90.00
Average
$113.00
High
$124.00
Current: $72.49
Latest ANIP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANIP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 16, 2026 | Guggenheim | Vamil Divan | Buy | Maintains | $124.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $100.00 |
| Nov 10, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $115.00 |
| Oct 9, 2025 | Truist Securities | Gregory Fraser | Hold | Maintains | $90.00 |
| Sep 24, 2025 | JP Morgan | Ekaterina Knyazkova | Overweight | Maintains | $115.00 |
| Sep 17, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $121.00 |
| Sep 8, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $114.00 |
| Aug 11, 2025 | Truist Securities | Gregory Fraser | Hold | Maintains | $77.00 |
| Aug 8, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $93.00 |
| Jul 10, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Initiates | $84.00 |
| May 12, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $86.00 |
| Apr 21, 2025 | Truist Securities | Gregory Fraser | Hold | Maintains | $65.00 |
| Apr 11, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $86.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
| Mar 14, 2025 | Jefferies | Glen Santangelo | Buy | Initiates | $80.00 |
| Mar 12, 2025 | JP Morgan | Ekaterina Knyazkova | Overweight | Initiates | $85.00 |
| Mar 5, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $86.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
| Dec 11, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $80.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $94.00 |
Ani Pharmaceuticals Inc. (ANIP) Competitors
The following stocks are similar to ANI Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANIP
ANI Pharmaceuticals
mkt cap
1.66B
Ani Pharmaceuticals Inc. (ANIP) Financial Data
Ani Pharmaceuticals Inc. has a market capitalization of $1.63B with a P/E ratio of 22.9x. The company generates $883.37M in trailing twelve-month revenue with a 8.9% profit margin.
Revenue growth is +29.6% quarter-over-quarter, while maintaining an operating margin of +12.0% and return on equity of +16.2%.
Valuation Metrics
Market Cap
$1.63B
Enterprise Value
$1.92B
P/E Ratio
22.9x
PEG Ratio
-0.1x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
+29.6%
Gross Margin
+59.4%
Operating Margin
+12.0%
Net Margin
+8.9%
EPS Growth
+29.6%
Financial Health
Cash/Price Ratio
+19.5%
Current Ratio
2.7x
Debt/Equity
116.2x
ROE
+16.2%
ROA
+3.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ani Pharmaceuticals Inc. (ANIP) Business Model
About Ani Pharmaceuticals Inc.
What They Do
Develops and markets prescription pharmaceuticals.
Business Model
ANI Pharmaceuticals operates by developing, manufacturing, and marketing both branded and generic prescription medications. The company generates revenue through its key segments, including Rare Disease, Generics, and Established Brands, focusing on a diverse range of dosage forms and therapeutic areas.
Additional Information
ANI Pharmaceuticals targets specialized markets primarily in the U.S. and Canada, emphasizing high-quality therapeutics and operational excellence. Founded in 2001 and based in Baudette, Minnesota, the company is involved in addressing significant patient needs with its innovative product offerings.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
897
CEO
Mr. Nikhil Lalwani
Country
United States
IPO Year
2000
Website
www.anipharmaceuticals.comAni Pharmaceuticals Inc. (ANIP) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
Mar 12, 2026
By Zacks Equity Research
Analyst Blog
Wall Street Analysts See a 44.84% Upside in ANI (ANIP): Can the Stock Really Move This High?
The mean of analysts' price targets for ANI (ANIP) points to a 44.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Mar 12, 2026
By Zacks Equity Research
Tale of the Tape
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data showing strong survival gains.
Mar 11, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
ANI Pharmaceuticals, Inc. (ANIP) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting key developments and strategic insights for investors.
Why It Matters
ANI Pharmaceuticals' presentation at a major healthcare conference signals potential insights into its strategy, pipeline developments, and financial outlook, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Wall Street Analysts See a 44.84% Upside in ANI (ANIP): Can the Stock Really Move This High?
1 day ago
Quick Summary
Analysts' price targets for ANI (ANIP) suggest a 44.8% upside. Increased consensus on earnings estimates indicates potential for stock growth.
Why It Matters
A 44.8% upside in price targets and consensus on raised earnings estimates suggest potential growth for ANI (ANIP), indicating positive sentiment and possible stock appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ANI (ANIP) has strong growth attributes that may enable it to outperform the market, according to recent news.
Why It Matters
ANI's strong growth potential suggests it may generate higher returns than the broader market, making it an attractive option for investors seeking performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ANI Pharmaceuticals reported Q4 and FY25 revenue growth of 30%, driven by Cortrophin Gel. Management maintains 2026 revenue guidance of $1.06-$1.12B, with potential near-term sales risks.
Why It Matters
ANI Pharmaceuticals' strong revenue growth highlights its market potential, yet near-term risks and dependence on Cortrophin sales could impact financial stability and future performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
ANI Pharmaceuticals, Inc. (ANIP) held its Q4 2025 earnings call, discussing financial performance and future outlook. For detailed results, refer to the full transcript.
Why It Matters
The Q4 2025 earnings call for ANI Pharmaceuticals provides insight into the company's financial performance, growth prospects, and operational challenges, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ANI Pharmaceuticals, Inc. reported its financial results and business highlights for Q4 and the full year of 2025 on February 27, 2026. Further details were not provided in the excerpt.
Why It Matters
ANI Pharmaceuticals' quarterly and annual financial results reveal company performance and growth potential, influencing stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ANIP Stock
What is Ani Pharmaceuticals Inc.'s (ANIP) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Ani Pharmaceuticals Inc. (ANIP) has a median price target of $113.00. The highest price target is $124.00 and the lowest is $90.00.
Is ANIP stock a good investment in 2026?
According to current analyst ratings, ANIP has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $72.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANIP stock?
Wall Street analysts predict ANIP stock could reach $113.00 in the next 12 months. This represents a 55.9% increase from the current price of $72.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ani Pharmaceuticals Inc.'s business model?
ANI Pharmaceuticals operates by developing, manufacturing, and marketing both branded and generic prescription medications. The company generates revenue through its key segments, including Rare Disease, Generics, and Established Brands, focusing on a diverse range of dosage forms and therapeutic areas.
What is the highest forecasted price for ANIP Ani Pharmaceuticals Inc.?
The highest price target for ANIP is $124.00 from Vamil Divan at Guggenheim, which represents a 71.1% increase from the current price of $72.49.
What is the lowest forecasted price for ANIP Ani Pharmaceuticals Inc.?
The lowest price target for ANIP is $90.00 from Gregory Fraser at Truist Securities, which represents a 24.2% increase from the current price of $72.49.
What is the overall ANIP consensus from analysts for Ani Pharmaceuticals Inc.?
The overall analyst consensus for ANIP is bullish. Out of 12 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $113.00.
How accurate are ANIP stock price projections?
Stock price projections, including those for Ani Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 6:25 AM UTC